Evidence map›Paper›PMID 42529345›Full record

ArticleJTO clinical and research reports2026

Clinical Activity of RET TKI Plus Chemotherapy After Progression on a RET TKI in a

Alvaro Guimaraes Paula, Ximeng Liu, Amirali Karimi, Kyle Concannon, Simon Heeke, Yasir Y Elamin, Kaiwen Wang, Jenny V Pozadzides, Natalie Vokes, Janet Tu and 11 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in JTO clinical and research reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Alvaro Guimaraes PaulaDepartment of Thoracic Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Ximeng LiuDepartment of Thoracic Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Amirali KarimiDepartment of Thoracic Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Kyle ConcannonDepartment of Thoracic Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Simon HeekeDepartment of Thoracic Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Yasir Y ElaminDepartment of Thoracic Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Kaiwen WangDivison of Pharmacy, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Jenny V PozadzidesDivision of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Natalie VokesDepartment of Thoracic Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Janet TuDivision of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Anne TsaoDepartment of Thoracic Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Marcelo V NegraoDepartment of Thoracic Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Jianjun ZhangDepartment of Thoracic Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Eric K SinghiDivision of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Bingman ZhangDepartment of Thoracic Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Waree RinsurongkawongDepartment of Quantitative Research Computing, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Isadora Guimaraes MartinsDepartment of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Hai T TranDepartment of Thoracic Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Don L GibbonsDepartment of Thoracic Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Monique B NilssonDepartment of Thoracic Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
John V HeymachDepartment of Thoracic Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Methods: This real-world retrospective cohort evaluated the outcomes of the combinations of chemotherapy with RETi (chemo/RETi) and chemotherapy with immunotherapy (chemo/IO) in patients with NSCLC who experienced progression while receiving RETi. For both groups, we assessed the overall response rate, using the Response Evaluation Criteria in Solid Tumors version 1.1; estimated progression-free survival (PFS) and overall survival using the Kaplan-Meier method; described the genomic features potentially related to RETi resistance; and analyzed safety data using the Common Terminology Criteria for Adverse Events version 5.0. Results: Overall, 12 patients were included. The median PFS was 7.8 months for patients receiving chemo/RETi ( Conclusions: Our data support the potential efficacy of chemo/RETi after progression on RETi, with significantly better PFS than chemo/IO, albeit with higher rates of hematologic toxicities.

Indexed as

ChemotherapyEfficacyNon–small cell lung cancerResistanceRET

Identifiers

PMID42529345
PMCPMC13416825

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.